Who is eligible for clinical trial NCT06179160?

Participants must meet the protocol's inclusion criteria for Solid Tumors. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06179160 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-20

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation

🩺 Plain-English Summary (8th-Grade Level)

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (7 items).

Location: Mayo Clinic Hospital — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

≥18 years old.
Locally advanced or metastatic solid tumor with KRAS G12D mutation.
For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
Cohort specific requirements aas defined in the protocol.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior treatment with any KRAS G12D inhibitor
Known additional invasive malignancy within 1 year of the first dose of study drug
History of organ transplant, including allogeneic stem cell transplantation
Significant, uncontrolled medical condition
History or presence of an ECG abnormality
Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

Mayo Clinic Hospital — Phoenix, Arizona
Stanford University — Palo Alto, California
UCLA Healthcare Hematology-Oncology — Santa Monica, California
Sarah Cannon Research Institue At Healthone — Denver, Colorado
Florida Cancer Specialists — Sarasota, Florida
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins — Baltimore, Maryland
Dana Farber Cancer Institute — Boston, Massachusetts
Hackensack University Medical Center — Hackensack, New Jersey
Weill Cornell Medicine — New York, New York
Memorial Sloan Kettering Cancer Center — New York, New York
Jefferson University Hospitals — Philadelphia, Pennsylvania
Scri Oncology Partners — Nashville, Tennessee
Md Anderson Cancer Center — Houston, Texas
Chris Obrien Lifehouse — Camperdown, New South Wales
St Vincent'S Hospital Sydney — Darlinghurst, New South Wales
Peter Maccallum Cancer Centre — Melbourne, Victoria
The Alfred Hospital — Melbourne, Victoria
Linear Clinical Research — Nedlands, Western Australia
Cliniques Universitaires Ucl Saint-Luc — Brussels,
Universitair Ziekenhuis Antwerpen (Uza) — Edegem,
Universitair Ziekenhuis (Uz) Leuven — Leuven,
The Ottawa Hospital Cancer Center — Ottawa, Ontario
Princess Margaret Cancer Center — Toronto, Ontario
Centre Leon Berard — Lyon,
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole — Toulouse,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors — Houston, Texas
Study of AUBE00 in Patients With Solid Tumors — Grand Rapids, Michigan
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors — Detroit, Michigan
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors — Los Angeles, California

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗